[go: up one dir, main page]

WO2006014911A3 - Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin - Google Patents

Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin Download PDF

Info

Publication number
WO2006014911A3
WO2006014911A3 PCT/US2005/026413 US2005026413W WO2006014911A3 WO 2006014911 A3 WO2006014911 A3 WO 2006014911A3 US 2005026413 W US2005026413 W US 2005026413W WO 2006014911 A3 WO2006014911 A3 WO 2006014911A3
Authority
WO
WIPO (PCT)
Prior art keywords
zinc
calprotectin
autoimmune
inflammatory
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/026413
Other languages
French (fr)
Other versions
WO2006014911A2 (en
Inventor
David C Kossor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2006014911A2 publication Critical patent/WO2006014911A2/en
Priority to US11/627,746 priority Critical patent/US20070275095A1/en
Anticipated expiration legal-status Critical
Publication of WO2006014911A3 publication Critical patent/WO2006014911A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Treatments are disclosed for various types of inflammatory, autoimmune, or other disorders characterized by excessive calprotectin, a protein that normally defends against microbial infections by sequestering available zinc at a site of infection. Capprotectin overactivity, leading to zinc deficiencies in localized tissues, can create or aggravate some autoimmune and/or inflammatory disorders, but efforts to provide systemic (oral) zinc supplements activate offsetting mechanisms and are ineffective. Therefore, targeted treatments are disclosed herein for suppresing and controlling excessive calprotectin activity in local tissues. Such methods include targeted injections of zinc solutions, and plasmapheresis treatment. Screening tests are also described for identifying non-protein drugs that can either (i) bind specifically to the zinc-binding sites of calprotectin, or (ii) suppress the release of calprotectin by neutrophil cells.
PCT/US2005/026413 2004-07-26 2005-07-26 Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin Ceased WO2006014911A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/627,746 US20070275095A1 (en) 2005-07-26 2007-01-26 Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59124104P 2004-07-26 2004-07-26
US60/591,241 2004-07-26

Publications (2)

Publication Number Publication Date
WO2006014911A2 WO2006014911A2 (en) 2006-02-09
WO2006014911A3 true WO2006014911A3 (en) 2009-04-02

Family

ID=35787759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/026413 Ceased WO2006014911A2 (en) 2004-07-26 2005-07-26 Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin

Country Status (1)

Country Link
WO (1) WO2006014911A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114062691B (en) * 2022-01-12 2022-04-01 苏州和锐生物科技有限公司 Diluent and calprotectin calibrator

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099635A1 (en) * 2001-10-04 2003-05-29 Protein Therapeutics, Inc. Use of oral gammaglobulin for the treatment of immune-mediated diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099635A1 (en) * 2001-10-04 2003-05-29 Protein Therapeutics, Inc. Use of oral gammaglobulin for the treatment of immune-mediated diseases

Also Published As

Publication number Publication date
WO2006014911A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
EP1712239A3 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2005027839A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
BR0308290A (en) Treatment and prevention of inflammatory disorders
WO2002015920A3 (en) Treatment of hyperproliferative diseases
WO2007146229A3 (en) Markers associated with arteriovascular events and methods of use thereof
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2007143098A8 (en) Hepatocyte growth factor (hgf) binding proteins
WO2007143090A3 (en) Hepatocyte growth factor (hgf) binding proteins
EP2712930A3 (en) Interferon alpha-induced pharmacodynamic markers
NO20044562L (en) Methods for treating bowel disease
WO2006034373A8 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
NO20076241L (en) Vascular disease therapies
AU2003223494A1 (en) Methods for detecting bcr-abl signaling activity in tissues using phospho- specific antibodies
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
TW200733974A (en) Materials and methods for treating chronic fibrotic disease
WO2005009366A3 (en) Restoring vascular function
WO2004075856A3 (en) Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
CY1116166T1 (en) NEW METHOD FOR TREATMENT OF H.PYLORI INFECTIONS
WO2006014911A3 (en) Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin
BRPI0514600A (en) methods for manufacturing a compound, for purifying a compound, for treating an individual having a neoplastic condition, having squamous cell carcinoma, and having basal cell carcinoma, for reducing or preventing the occurrence of a neoplastic condition in an individual, and for the reduction of serum triglycerides in an individual, compound, and, pharmaceutical composition
WO2005089449A3 (en) Methods for treating alcoholism
WO2008006187A3 (en) Protein complexes for prevention and treatment of diseases with angiogenesis disorders
WO2006042017A3 (en) Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
BRPI0720158A2 (en) DISSEMINATED INTRAVASCULAR COAGULATION THERAPY AND / OR IMPROVEMENT AGENTS, TO REDUCE THE PROBABILITY OF DEATH IN PATIENTS SUFFERING FROM THE SAME, METHODS FOR SELECTING PATIENTS, AND TO TREAT AND / OR IMPROVE INTRAVASCULAR COAGULATION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase